Iparomlimab/Tuvonralimab
Phase 2Monoclonal antibody
Iparomlimab/Tuvonralimab is one of 98 small molecule programs targeting Tuvonralimab. It is currently in Phase 2.
3
Indications
4
Total Trials
4
Active Trials
97
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Tecentriq
RochePhase 3
Mfolfox6
RochePhase 3
Trifluridine/tipiracil
AbbViePhase 3
Botensilimab
AAgenus Inc.
Phase 3
Zanzalintinib
Merck & Co.Phase 3
XL092
RochePhase 3
TAS 102
Taiho Oncology, Inc.Phase 3
Leucovorin and 5-FU
AAkeso
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Cancer2 trials
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07454018·45 enrolled
Tuvonralimab1 trial
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Recruiting·—·Phase 2·NCT07232654·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iparomlimab/Tuvonralimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details